Loading…
Reported covered position: Scheduler, Rep. Jason Altmire (D-PA); Director of Operations, Rep. Mike Thompson (D-CA)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019
S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMERICAN TELEMEDICINE ASSOCIATION via FAEGRE BAKER DANIELS CONSULTING
2019 · third_quarter · Q3
Telemedicine legislation including the RUSH Act; CONNECT Act; Ryan Haight Act
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
COALITION FOR A SECURE AND TRANSPARENT INTERNET via FAEGRE BAKER DANIELS CONSULTING
2019 · third_quarter · Q3
Source: Senate LDA
| AMERICAN TELEMEDICINE ASSOCIATION |
| 2 |
| 2019 |
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
HR 2507 - Newborn Screening Saves Lives Reauthorization Act of 2019; Vaccine policy.
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
HR 2507 - Newborn Screening Saves Lives Reauthorization Act of 2019; Vaccine policy.
Concentrating on High-value Alzheimer’s Needs to Get to an End (CHANGE) Act of 2019
Client: USAGAINST ALZHEIMER'S · Firm: FAEGRE BAKER DANIELS CONSULTING
S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019
Concentrating on High-value Alzheimer’s Needs to Get to an End (CHANGE) Act of 2019
Client: USAGAINST ALZHEIMER'S · Firm: FAEGRE BAKER DANIELS CONSULTING
S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019
Access to Marketplace Insurance Act
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); H.R. 3976 (Access to Marketplace Insurance Act)
Access to Marketplace Insurance Act
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); H.R. 3976 (Access to Marketplace Insurance Act)
Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGAINST ALZHEIMER'S · Firm: FAEGRE BAKER DANIELS CONSULTING
S. 2387, H.R. 4957: Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGAINST ALZHEIMER'S · Firm: FAEGRE BAKER DANIELS CONSULTING
S. 2387, H.R. 4957: Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
Removing Barriers to Allergy Diagnostic Testing Act of 2018
Client: THERMO FISHER SCIENTIFIC · Firm: FAEGRE BAKER DANIELS CONSULTING
Asthma policies and diagnostic allergy test coverage; H.R. 5541 - Removing Barriers to Allergy Diagnostic Testing Act of 2018
Removing Barriers to Allergy Diagnostic Testing Act of 2018
Client: THERMO FISHER SCIENTIFIC · Firm: FAEGRE BAKER DANIELS CONSULTING
Asthma policies and diagnostic allergy test coverage; H.R. 5541 - Removing Barriers to Allergy Diagnostic Testing Act of 2018
Medicare Home Infusion Therapy Access Act of 2017
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); evaluation of IVIG Demonstration
Medicare Home Infusion Therapy Access Act of 2017
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); H.R. 3976 (Access to Marketplace Insurance Act)
Medicare Home Infusion Therapy Access Act of 2017
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); evaluation of IVIG Demonstration
Medicare Home Infusion Therapy Access Act of 2017
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); H.R. 3976 (Access to Marketplace Insurance Act)
Concentrating on High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGAINST ALZHEIMER'S · Firm: FAEGRE BAKER DANIELS CONSULTING
S. 2387, H.R. 4957: Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
Concentrating on High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGAINST ALZHEIMER'S · Firm: FAEGRE BAKER DANIELS CONSULTING
S. 2387, H.R. 4957: Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
Medicare Home Infusion Therapy Access Act of 2017
Client: IMMUNE DEFICIENCY FOUNDATION · Firm: FAEGRE BAKER DANIELS CONSULTING
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act)
Advocate for public access to transparent, non-anonymous WHOIS data
Filing targets: HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2019 · third_quarter · Q3
S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019
Fiscal Year 2020 funding for Alzheimer's disease research and policies to enhance NIH Alzheimer's research.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THERMO FISHER SCIENTIFIC via FAEGRE BAKER DANIELS CONSULTING
2019 · third_quarter · Q3
Drug shortages
Fiscal Year 2019 labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship.
Asthma policies and diagnostic allergy test coverage; Removing Barriers to Allergy Diagnostics Testing Act of 2019
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · third_quarter · Q3
Increasing funding for Myotonic Dystrophy research; Fiscal Year 2019 Labor and HHS appropriations.
Fiscal Year 2019 Defense appropriations legislation; Peer Review Medical Research Program and Congressionally Directed Medical Research Program
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · third_quarter · Q3
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; implementation of home infusion services payment; coding and coverage of forms of primary immunodeficiency (PI) Disease; concerns regarding self-administered drugs list and home infusion payment
HR 2507 - Newborn Screening Saves Lives Reauthorization Act of 2019; Vaccine policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2019 · second_quarter · Q2
S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019
Fiscal Year 2020 funding for Alzheimer's disease research and policies to enhance NIH Alzheimer's research.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · second_quarter · Q2
HR 2507 - Newborn Screening Saves Lives Reauthorization Act of 2019; Vaccine policy.
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; implementation of home infusion services payment; coding and coverage of forms of primary immunodeficiency (PI) Disease.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
THERMO FISHER SCIENTIFIC via FAEGRE BAKER DANIELS CONSULTING
2019 · second_quarter · Q2
Drug shortages
Asthma policies and diagnostic allergy test coverage; Removing Barriers to Allergy Diagnostics Testing Act of 2019
Fiscal Year 2019 labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · second_quarter · Q2
Increasing funding for Myotonic Dystrophy research; Fiscal Year 2019 Labor and HHS appropriations.
Fiscal Year 2019 Defense appropriations legislation; Peer Review Medical Research Program and Congressionally Directed Medical Research Program
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
AMERICAN TELEMEDICINE ASSOCIATION via FAEGRE BAKER DANIELS CONSULTING
2019 · second_quarter · Q2
Telemedicine legislation including the RUSH Act; CONNECT Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR A SECURE AND TRANSPARENT INTERNET via FAEGRE BAKER DANIELS CONSULTING
2019 · second_quarter · Q2
Advocate for public access to transparent, non-anonymous WHOIS data
Filing targets: HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), SENATE
THERMO FISHER SCIENTIFIC via FAEGRE BAKER DANIELS CONSULTING
2019 · first_quarter · Q1
Fiscal Year 2019 labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship.
Drug shortages
Asthma policies and diagnostic allergy test coverage; Removing Barriers to Allergy Diagnostics Testing Act of 2019
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2019 · first_quarter · Q1
General issues regarding Alzheimer's Disease
Work to revise and reintroduce the Concentrating on High-Value Alzheimer's Needs to Get to and End (CHANGE) Act.
Fiscal Year 2020 funding for Alzheimer's disease research and policies to enhance NIH Alzheimer's research.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · first_quarter · Q1
Patient access to medications; general overview of primary immunodeficiency (PI) community.
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; implementation of home infusion services payment; coding and coverage of forms of primary immunodeficiency (PI) Disease.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2019 · first_quarter · Q1
Increasing funding for Myotonic Dystrophy research; Fiscal Year 2019 Labor and HHS appropriations.
Fiscal Year 2019 Defense appropriations legislation; Peer Review Medical Research Program and Congressionally Directed Medical Research Program
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
COALITION FOR A SECURE AND TRANSPARENT INTERNET via FAEGRE BAKER DANIELS CONSULTING
2019 · first_quarter · Q1
Advocate for public access to transparent, non-anonymous WHOIS data
Filing targets: HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), SENATE
THERMO FISHER SCIENTIFIC via FAEGRE BAKER DANIELS CONSULTING
2018 · fourth_quarter · Q4
Drug shortage prevention and abuse-deterrent pseudophedrine.
Fiscal year 2019 VA and labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship
Asthma policies and diagnostic allergy test coverage; H.R. 5541 - Removing Barriers to Allergy Diagnostic Testing Act of 2018
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · fourth_quarter · Q4
Increasing funding for Myotonic Dystrophy research; Fiscal year 2019 labor and HHS appropriations
Fiscal year 2019 defense appropriations legislation; Peer Review Medical Research Program and Congressional Directed Medical Research Program
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
SCIENTIST via FAEGRE BAKER DANIELS CONSULTING
2018 · fourth_quarter · Q4
Digital marketplace for research and development services.
Filing targets: HOUSE OF REPRESENTATIVES
COALITION FOR A SECURE AND TRANSPARENT INTERNET via FAEGRE BAKER DANIELS CONSULTING
2018 · fourth_quarter · Q4
Advocate for public access to transparent, non-anonymous WHOIS data
Filing targets: HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2018 · fourth_quarter · Q4
General issues regarding Alzheimer's Disease
Fiscal year 2019 funding for Alzheimer's disease research
S. 2387, H.R. 4957: Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · fourth_quarter · Q4
Patient access to medications; access to insurance coverage; patient protections in AHCA and BCRA; health care reform
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); evaluation of IVIG Demonstration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
THERMO FISHER SCIENTIFIC via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · Q3
Fiscal year 2019 VA and labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship
Asthma policies and diagnostic allergy test coverage; H.R. 5541 - Removing Barriers to Allergy Diagnostic Testing Act of 2018
Drug shortage prevention and abuse-deterrent pseudophedrine.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · Q3
Increasing funding for Myotonic Dystrophy research; Fiscal year 2019 labor and HHS appropriations
Fiscal year 2019 defense appropriations legislation; Peer Review Medical Research Program and Congressional Directed Medical Research Program
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
COALITION FOR A SECURE AND TRANSPARENT INTERNET via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · 3A
Advocate for public access to transparent, non-anonymous WHOIS data
Filing targets: HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), SENATE
SCIENTIST via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · Q3
Digital marketplace for research and development services.
Filing targets: HOUSE OF REPRESENTATIVES
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · Q3
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); evaluation of IVIG Demonstration
Patient access to medications; access to insurance coverage; patient protections in AHCA and BCRA; health care reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · Q3
S. 2387, H.R. 4957: Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
Fiscal year 2019 funding for Alzheimer's disease research
General issues regarding Alzheimer's Disease
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
SCIENTIST via FAEGRE BAKER DANIELS CONSULTING
2018 · third_quarter · RR
Digital marketplace for research and development services
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2018 · second_quarter · Q2
Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
Fiscal year 2019 labor HHS appropriations
Alzheimer's Disease research
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · second_quarter · Q2
Increasing funding for Myotonic Dystrophy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · second_quarter · Q2
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); H.R. 3976 (Access to Marketplace Insurance Act)
Patient access to medications; access to insurance coverage; patient protections in AHCA and BCRA; health care reform
Appropriations for NIH
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC DYSTROPHY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · first_quarter · 1A
Increasing funding for Myotonic Dystrophy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2018 · first_quarter · Q1
Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act
Fiscal year 2018 and 2019 appropriations for Alzheimers Disease research
General issues regarding Alzheimer's Disease
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2018 · first_quarter · Q1
Appropriations for NIH
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act); H.R. 3976 (Access to Marketplace Insurance Act)
Patient access to medications; access to insurance coverage; patient protections in AHCA and BCRA; health care reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
USAGAINST ALZHEIMER'S via FAEGRE BAKER DANIELS CONSULTING
2017 · fourth_quarter · Q4
Alzheimer's Disease research
Policies to support beneficiaries with AD
General issues regarding Alzheimer's Disease
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · fourth_quarter · Q4
Appropriations for NIH
Patient access to medications; access to insurance coverage; patient protections in AHCA and BCRA; health care reform
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; S. 1738 (Medicare Home Infusion Therapy Access Act)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IMMUNE DEFICIENCY FOUNDATION via FAEGRE BAKER DANIELS CONSULTING
2017 · third_quarter · Q3
Appropriations for NIH
Medicare coverage and payment for immune globulin (IG) treatments; Part B reimbursement issues; IVIG Access Act
Patient access to medications; access to insurance coverage; patient protections in AHCA and BCRA; health care reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues regarding Alzheimer's Disease
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Alzheimer's Disease research
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Appropriations for Alzheimers research
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE